6.5 C
New York
Saturday, March 6, 2021

Novavax announces the readiness of a new vaccine against coronavirus

Must Read

Scientists discover a pathogen (more dangerous than coronavirus) killing endangered chimpanzees

The disease has a 100% mortality rate in Sierra Leone primates. The researchers worry the bacteria could pass to humans On...

What will Neutron look like, the new rocket for interplanetary human missions that will compete with SpaceX

The 8-ton, reusable ship was created by Rocket Lab, an aerospace startup founded in New Zealand, which seeks to...

The 5 AM Club: what the millionaires’ morning routine is like

Leaders like Steve Jobs surrendered to the motivational ideas of Robin Sharma, one of the world's most renowned leadership...
Manish Saini
Manish works as a Journalist and writer at Revyuh.com. He has studied Political Science and graduated from Delhi University. He is a Political engineer, fascinated by politics, and traditional businesses. He is also attached to many NGO's in the country and helping poor children to get the basic education. Email: Manish (at) revyuh (dot) com

Novavax COVID-19 Vaccine shows 89.3% efficacy and more than 15 thousand people aged 18 to 84 took part in the clinical trials, including 27% over 65

According to the results of the third phase of clinical trials, the effectiveness of the vaccine of the American biotechnological company Novavax was 89.3%. This was announced on Thursday, January 28, by the press release.

“The vaccine against COVID-19, according to the results of the third phase of clinical trials conducted in the UK, showed an effectiveness of 89.3%,” the manufacturer said in a statement.

It is specified that more than 15 thousand people aged 18 to 84 took part in the tests, 27% of them were over 65 years old.

Last July, Novavax announced that the US administration had allocated $ 1.6 billion to develop a vaccine against the coronavirus. The first phase of human clinical trials of this vaccine began in May in Melbourne, Australia.

In November, Bloomberg presented a ranking of the demand for vaccines against coronavirus. 

Novavax was at the second place in the number of pre-orders (1.4 billion doses, of which 160 million – the USA, 100 million – Europe), the third – Johnson & Johnson (1.3 billion doses, of which 430 million – the United States, 300 million – European countries). 

Most of the purchases in the world are for the vaccine of the British company AstraZeneca.

- Advertisement -
- Advertisement -

Latest News

Scientists discover a pathogen (more dangerous than coronavirus) killing endangered chimpanzees

The disease has a 100% mortality rate in Sierra Leone primates. The researchers worry the bacteria could pass to humans On...
- Advertisement -

More Articles Like This

- Advertisement -